Chen Yi, Chen Xiao-Song, He Rong-Quan, Huang Zhi-Guang, Lu Hui-Ping, Huang Hong, Yang Da-Ping, Tang Zhong-Qing, Yang Xia, Zhang Han-Jie, Qv Ning, Kong Jin-Liang, Chen Gang
Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
World J Clin Oncol. 2024 Jun 24;15(6):765-782. doi: 10.5306/wjco.v15.i6.765.
Lung cancer bone metastasis (LCBM) is a disease with a poor prognosis, high risk and large patient population. Although considerable scientific output has accumulated on LCBM, problems have emerged, such as confusing research structures.
To organize the research frontiers and body of knowledge of the studies on LCBM from the last 22 years according to their basic research and translation, clinical treatment, and clinical diagnosis to provide a reference for the development of new LCBM clinical and basic research.
We used tools, including R, VOSviewer and CiteSpace software, to measure and visualize the keywords and other metrics of 1903 articles from the Web of Science Core Collection. We also performed enrichment and protein-protein interaction analyses of gene expression datasets from LCBM cases worldwide.
Research on LCBM has received extensive attention from scholars worldwide over the last 20 years. Targeted therapies and immunotherapies have evolved into the mainstream basic and clinical research directions. The basic aspects of drug resistance mechanisms and parathyroid hormone-related protein may provide new ideas for mechanistic study and improvements in LCBM prognosis. The produced molecular map showed that ribosomes and focal adhesion are possible pathways that promote LCBM occurrence.
Novel therapies for LCBM face animal testing and drug resistance issues. Future focus should centre on advancing clinical therapies and researching drug resistance mechanisms and ribosome-related pathways.
肺癌骨转移(LCBM)是一种预后差、风险高且患者群体庞大的疾病。尽管在LCBM方面已经积累了大量的科学研究成果,但也出现了一些问题,比如研究结构混乱。
根据过去22年关于LCBM的基础研究与转化、临床治疗以及临床诊断等方面,梳理其研究前沿和知识体系,为LCBM新的临床和基础研究发展提供参考。
我们使用了包括R、VOSviewer和CiteSpace软件在内的工具,来测量和可视化来自科学引文索引核心合集的1903篇文章的关键词及其他指标。我们还对全球范围内LCBM病例的基因表达数据集进行了富集分析和蛋白质-蛋白质相互作用分析。
在过去20年里,LCBM研究受到了全球学者的广泛关注。靶向治疗和免疫治疗已成为主流的基础和临床研究方向。耐药机制和甲状旁腺激素相关蛋白的基础研究方面可能为LCBM的机制研究和预后改善提供新思路。生成的分子图谱表明核糖体和粘着斑是促进LCBM发生的可能途径。
LCBM的新型治疗面临动物试验和耐药性问题。未来的重点应集中在推进临床治疗以及研究耐药机制和核糖体相关途径上。